Some inexperienced, no name guy won that year, right?

10/10 Highly recommend

This may be worth pushing back against, particularly if you can one or more reputable sources that make a case for the benefits of writing from a 1st person perspective.

This tracks. With the exception of written equations, abbreviations usually serve the author more than the reader.

Underline, bold, and italicize sporadically to help the reviewers understand what's most important.

What's always been frustrating about the indirect cost issue as a PI is that we rarely have any idea how the actual rate is calculated. I'd love to be more confident about the actual costs and how close the negotiated rate comes to covering these costs (both averaged across the institution).

Perhaps the key question here is what should we, as biomedical researchers, be advocating for in the long run with regard to budgeting for direct/indirect costs?

Aside from assuming a constant NIH budget, the other core assumption here is that indirect rates are truly higher than what is strictly necessary for a given project. If anyone knows of a rigorous financial analysis of true f&a costs, please share.

One possible outcome of a reallocation is an increase in overall funding rates, and an increase in the number of funded investigators.